181633-36-3

Basic information

• Product Name: 3-fluoro-5-(3'-pyridyl)phenylamine
• Synonyms: 3-fluoro-5-(3'-pyridyl)phenylamine
• CAS NO: 181633-36-3
• Molecular Weight: 188.204
• Mol File: 181633-36-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-fluoro-5-(3'-pyridyl)phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-5-(3'-pyridyl)phenylamine(181633-36-3)
• EPA Substance Registry System: 3-fluoro-5-(3'-pyridyl)phenylamine(181633-36-3)

Safety Data

• Hazardous Substances Data: 181633-36-3(Hazardous Substances Data)

Upstream product

• 1237588-06-5 C₁₁H₇ClFN 
• 1692-25-7 3-pyridylboronic acid 
• 134168-97-1 3-bromo-5-fluoroaniline 
• 3819-88-3 1-fluoro-3-iodo-5-nitrobenzene 

Downstream Products

• 264616-97-9 phenyl N-[3-fluoro-5-(3-pyridyl)phenyl]carbamate 
• 181629-93-6 SB 228357 

Relevant articles and documents

An electroluminescent compound and an electroluminescent device comprising the same

The present invention relates to an organic light emitting compound represented by chemical formula 1, and having an asymmetrical structure according to L---Landprime;. The organic light emitting compound has excellent light emitting efficiency and a life

NOVEL CATALYSTS

The present invention provides novel compounds and ligands that are useful in transition metal catalyzed cross-coupling reactions. For example, the compounds and ligands of the present invention are useful in palladium or gold catalyzed cross-coupling reactions.

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3- pyridyl)oxy]5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent

The evolution, synthesis, and biological activity of a novel series of 5-HT(2C) receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT(2C) affinity and selectivity over 5- HT(2A) receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT(2B) receptor. Compounds from this series are inverse agonists at the human cloned 5-HT(2C) receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.